Results 151 to 160 of about 11,830 (209)

HLA-DQB1*03:01 and HLA-DQA1*05:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease. [PDF]

J Gastroenterol
Osaka R, Naito T, Khor SS, Kakuta Y, Kawai Y, Nagasaki M, Meguro H, Iwaki H, Okamoto D, Nagai H, Shimoyama Y, Moroi R, Shiga H, Kinouchi Y, Masamune A.   +14 more
europepmc   +1 more source

Pharmacogenetic Analysis of TPMT and NUDT15 in a European Pediatric Cohort with IBD and Autoimmune Diseases: Frequency Data and Clinical Relevance. [PDF]

Genes (Basel)
Pau A, Galliano I, Ponte A, Clemente A, Dini M, Calvi C, Montanari P, Pizzol A, Gambarino S, Calvo PL, Bergallo M.   +10 more
europepmc   +1 more source

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care. [PDF]

Pharmacogenomics
Bernsen EC, Hanff LM, Kouwenberg TW, Hagleitner MM, Tops BBJ, Biesot N, Hehir-Kwa JY, Huitema ADR, Diekstra MHM.   +8 more
europepmc   +1 more source

Vedolizumab in inflammatory bowel disease: pharmacokinetics and the role of immunomodulator co-therapy. [PDF]

Ther Adv Gastroenterol
Pudipeddi A, Chaemsupaphan T, Arzivian A, Kim YS, Paramsothy S, Kariyawasam V, Leong RW.   +6 more
europepmc   +1 more source

A guide to healthcare maintenance for the patient with inflammatory bowel disease. [PDF]

Ann Gastroenterol
Jaoude CRB, Bitar ER, Mourad FH, Gnanapandithan K, Farraye FA, Hashash JG.   +5 more
europepmc   +1 more source

[Pharmacogenetic study of thiopurine S-methyltransferase (TPMT) and thiopurine toxicity].

Revista espanola de enfermedades digestivas, 2003
H, Corominas, C, Díaz, G, Vázquez, M, Baiget   +3 more
openaire   +1 more source

Thiopurines and IBD

, 2007
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Clinical Impact of Thiopurine Methyltransferase Polymorphisms on Thiopurine Treatment

Nucleosides, Nucleotides and Nucleic Acids, 2004
Acute lymphoblastic leukaemia (ALL) is the most common malignancy of childhood. Although current treatment results in long term survival in over 70% of cases there is evidence that as many as 50% could have been cured using a less complex regimen with a lower incidence of long term side effects.
A G Hall
exaly   +3 more sources

Thiopurine toxicity

British Journal of Hospital Medicine, 2013
Thiopurines are a class of immunosuppressant and antineoplastic drugs developed by Gertrude Elion and George Hitchings and patented in 1953 for use to treat leukaemia, then used to prevent transplant rejection (Marx, 2005).
Kl, de Wit, Be, White, D, Goldsmith
openaire   +3 more sources